Search
Search Results
-
Time to Reach Glycaemic and Body Weight Loss Thresholds with Tirzepatide in Patients with Type 2 Diabetes: A Pre-planned Exploratory Analysis of SURPASS-2 and SURPASS-3
IntroductionTirzepatide, a once-weekly glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 receptor agonist, provides clinically...
-
Patient-Reported Outcomes in People with Type 2 Diabetes Receiving Tirzepatide in the SURPASS Clinical Trial Programme
IntroductionTirzepatide, a novel glucose-dependent insulinotropic polypeptide and glucagon-like peptide 1 receptor agonist, is approved for glycaemic...
-
Barriers and facilitators to the implementation of a new European eHealth solution (SurPass v2.0): the PanCareSurPass Open Space study
PurposeTo identify barriers and facilitators for implementing the Survivorship Passport (SurPass) v2.0 in six long-term follow-up (LTFU) care centres...
-
A systematic review and meta-analysis of Surpass flow diverter for the treatment of intracranial aneurysms
ObjectiveSystematically review and analyze the published literature on the safety and efficacy of Surpass flow diverter in terms of mortality,...
-
Systolic blood pressure reduction with tirzepatide in patients with type 2 diabetes: insights from SURPASS clinical program
BackgroundTirzepatide, a once-weekly glucose-dependent insulinotropic polypeptide/ glucagon-like peptide-1 receptor agonist, is approved in the...
-
Barriers and facilitators to implementation of the interoperable Survivorship Passport (SurPass) v2.0 in 6 European countries: a PanCareSurPass online survey study
PurposeLong-term follow-up (LTFU) care for childhood cancer survivors (CCSs) is essential to improve and maintain their quality of life. The...
-
Efficacy and Safety of Tirzepatide in Patients with Type 2 Diabetes: Analysis of SURPASS-AP-Combo by Different Subgroups
IntroductionTirzepatide is a novel glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist. In the SURPASS-AP-Combo...
-
Reduction of prevalence of patients meeting the criteria for metabolic syndrome with tirzepatide: a post hoc analysis from the SURPASS Clinical Trial Program
BackgroundMetabolic syndrome is characterized as the co-occurrence of interrelated cardiovascular risk factors, including insulin resistance,...
-
Metabolic Abnormalities Following Tirzepatide Monotherapy in Japanese Patients with Type 2 Diabetes: A Phase 3 SURPASS J-mono Post Hoc Analysis
IntroductionThe presence of metabolic abnormalities in patients with type 2 diabetes (T2D) increases the risk of cardiovascular disease and other...
-
Ultra-Early “Fishmouth stenosis” and thrombosis of a Surpass Evolve flow diversion device following treatment of multiples right siphon aneurysms
We present a case of ultra-early symptomatic fish-mouth type stenosis (FMTS) of a Surpass Evolve flow diverter stent (SE-FDS) occurring within 24 h...
-
Treatment Satisfaction and Quality of Life with Tirzepatide Versus Dulaglutide Among Japanese Patients with Type 2 Diabetes: Exploratory Evaluation of the SURPASS J-mono Trial
IntroductionTreatment satisfaction in diabetes management is vital to achieving long-term clinical outcomes. This analysis evaluated treatment...
-
Early clinical experience of using the Surpass Evolve flow diverter in the treatment of intracranial aneurysms
PurposeHere, we presented our early experience with flow diversion procedures using the Surpass Evolve flow diverter (SE, Stryker) and reported the...
-
Parental Relationships Surpass Friendships as Predictors of Long-Term Mental Functioning: A Multilevel Analysis
There were associations between interpersonal relationships (parental relationships and friendships) and mental functioning (depressive symptoms,...
-
Initial Experience with Surpass Evolve Flow Diverter in the Treatment of Intracranial Aneurysms
Background and PurposeThe principle of flow diversion has revolutionized the treatment of brain aneurysms. In this study, we report our experience of...
-
The Role of Tirzepatide, Dual GIP and GLP-1 Receptor Agonist, in the Management of Type 2 Diabetes: The SURPASS Clinical Trials
Glucagon-like peptide 1 (GLP-1) based therapy is an established treatment option for the management of type 2 diabetes mellitus (T2DM) and is...
-
Ultrasonic spleen thickness-based indexes surpass Baveno VI criteria in high-risk gastroesophageal varices detection
AimsTo evaluate the efficiency of ultrasonic spleen thickness (UST), routine variables and (expanded) Baveno VI criteria for high-risk...
-
Improved Glycaemic and Weight Management Are Associated with Better Quality of Life in People with Type 2 Diabetes Treated with Tirzepatide
IntroductionLimited data are available on the relationship between quality of life (QoL) change and significant degrees of reduction in glycated...
-
The impact and prevention of systemic and diagnostic errors in surgical malpractice claims in Japan: a retrospective cohort study
The Surgical Patient Safety System (SURPASS) has been proven to improve patient outcomes. However, few studies have evaluated the details of...
